KOREA WHO
-
-
-
CEO of Onconic Therapeutics
John Kim
Veteran Drug Developer Leads Global Push with Jaqbo
-
Last Updated on Jun 18, 2025
-
CEO of Onconic Therapeutics
Life Summary
John Kim (Korean name: Kim Jung-hoon) is the CEO of Onconic Therapeutics.
He is focusing on expanding into the global market with Jaqbo, a treatment for gastroesophageal reflux disease. He is also accelerating the research and development of another core pipeline drug, Nesuparib.
Kim was born on November 18, 1967.
He graduated from Simon Fraser University in Canada and earned both his master's and doctoral degrees in clinical pharmacy from the University of British Columbia.
Since 1997, he has worked as a researcher at Biogen in the United States and Boehringer Ingelheim in Germany. He later joined LG Life Sciences as Head of Clinical Development, and then moved to Hanmi Pharmaceutical as Director of Global Clinical Development. He also served as Head of Business Development for the Asia-Pacific region at Mundipharma.
In 2015, he was appointed CEO of SeoulCRO, a clinical trial-focused affiliate of CHA Biotech, and also lectured as a professor at CHA University and the College of Pharmacy at Sungkyunkwan University. In 2020, he became CEO of Onconic Therapeutics.
Kim is a clinical development expert who has worked across the full spectrum of new drug development, including drug discovery, domestic and international clinical trials, and global business development.
He has led the research and development of Jaqbo, a treatment for gastroesophageal reflux disease.
#OnconicTherapeutics #KimJungHoon #Jaqbo #gastroesophagealreflux #biotech #clinicaltrials #newdrugdevelopment #Nesuparib #globalpharma #CEO
He is focusing on expanding into the global market with Jaqbo, a treatment for gastroesophageal reflux disease. He is also accelerating the research and development of another core pipeline drug, Nesuparib.
Kim was born on November 18, 1967.
He graduated from Simon Fraser University in Canada and earned both his master's and doctoral degrees in clinical pharmacy from the University of British Columbia.
Since 1997, he has worked as a researcher at Biogen in the United States and Boehringer Ingelheim in Germany. He later joined LG Life Sciences as Head of Clinical Development, and then moved to Hanmi Pharmaceutical as Director of Global Clinical Development. He also served as Head of Business Development for the Asia-Pacific region at Mundipharma.
In 2015, he was appointed CEO of SeoulCRO, a clinical trial-focused affiliate of CHA Biotech, and also lectured as a professor at CHA University and the College of Pharmacy at Sungkyunkwan University. In 2020, he became CEO of Onconic Therapeutics.
Kim is a clinical development expert who has worked across the full spectrum of new drug development, including drug discovery, domestic and international clinical trials, and global business development.
He has led the research and development of Jaqbo, a treatment for gastroesophageal reflux disease.
#OnconicTherapeutics #KimJungHoon #Jaqbo #gastroesophagealreflux #biotech #clinicaltrials #newdrugdevelopment #Nesuparib #globalpharma #CEO